ArticleJACC. Case reports2026
Transcatheter Tricuspid Valve Replacement in a Heart Transplant Recipient.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ventricular Volumetric Changes After Transcatheter Tricuspid Valve Replacement in a Heart Transplant Recipient.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter tricuspid valve replacement (TTVR) is an emerging therapy for patients with severe tricuspid regurgitation (TR) who are often at prohibitive surgical risk. Orthotopic heart transplant recipients represent a particularly high-risk subgroup, frequently excluded from surgical intervention and underrepresented in clinical trials. CASE SUMMARY: We present one of the inaugural cases of TTVR using the EVOQUE valve system (Edwards Lifesciences) in an orthotopic heart transplant recipient with severe TR. The procedure was completed successfully without complications, yielding a well-seated prosthetic valve with no significant paravalvular leak and marked reduction in TR. The patient demonstrated significant clinical improvement, with functional status improving to NYHA functional class II. DISCUSSION: This case illustrates the feasibility and safety of the EVOQUE TTVR system in complex, high-risk patients. Importantly, it highlights the potential of this therapy in heart transplant recipients with torrential TR, a challenging population with limited therapeutic options. TAKE-HOME MESSAGES: The EVOQUE TTVR system appears to be a safe and feasible treatment option for orthotopic heart transplant recipients with severe or torrential TR, even in the setting of prior failed transcatheter edge-to-edge repair and challenging right heart anatomy. Multimodality imaging (transesophageal echocardiography, intracardiac echocardiography, and computed tomography) plays a critical role in procedural planning and guidance for complex TTVR cases, helping optimize outcomes in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.